The DES (diethylstilbestrol) years: Bridging the past into the future

Primary Care Update for Ob/Gyns

Volumn 9, Issue 1, 2002, Pages 7-12

  Martino, Martin A ^a,b   Nevadunsky, Nicole S ^a   Magliaro, Thomas J ^a   Goldberg, Michael I ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b SAINT PETER S UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; PROTEIN P53; STEROID;

ADENOCARCINOMA; ALTERNATIVE MEDICINE; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER INHIBITION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DIABETES MELLITUS; DNA MODIFICATION; DRUG EXPOSURE; DRUG INDUCED DISEASE; EVIDENCE BASED MEDICINE; HASHIMOTO DISEASE; HIGH RISK PREGNANCY; HUMAN; HYPERTENSION; MUTATION; NONHUMAN; PATHOPHYSIOLOGY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPONTANEOUS ABORTION; SURVIVAL RATE; TERATOGENICITY; TUMOR SUPPRESSOR GENE; VAGINA CANCER;

EID: 0036169989     PISSN: 1068607X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1068-607X(01)00095-6     Document Type: Article

References (29)

1. Diethylstilbestrol revisited: A review of the long-term health effects
2. Adenocarcinoma of the vagina: An association of maternal stilbestrol therapy with tumor appearance in young women
3. Vaginal cancer
4. Breast cancer in mothers given diethylstilbestrol in pregnancy
5. Diethystilbestrol in the prevention and treatment of complications of pregnancy
6. The influence of diethystilbestrol on the progress and outcome of pregnancy as based on a comparison of treated with untreated primigravidas
7. Mammary carcinomas in mice following oral administration of stilbestrol
8. Does the administration of diethystilbestrol during pregnancy have therapeutic value?
9. Rates and risks of diethystilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update
10. Postcoital contraception with diethylstilbestrol
11. Clear cell adenocarcinoma of the vagina and cervix: Incidence, undetected diseases, and DES
12. In utero diethystilbestrol (DES) exposure alters Hox gene expression in the developing mullerian system
13. Human papillomavirus detection and p53 expression in clear-cell adenocarcinoma of the vagina and cervix
14. Dysplasia and cytologic findings in 4,589 young women enrolled in Diethystilbestrol-Adenosis (DESAD) Project
15. Topographic relation of cervical ectropion and vaginal adenosis to clear cell adenocarcinoma
16. Development of cervical and vaginal squamous cell neoplasia as a later consequence of in utero exposure to diethylstilbestrol
17. Upper genital tract changes and pregnancy outcome in offspring exposed in utero to diethylstilbestrol
18. Reproductive and gynecologic surgical experience in diethylstilbestrol-exposed daughters
19. Clear-cell adencocarcinoma of the vagina and cervix in girls: Analysis of 170 registry cases
20. Comprehensive gynecology
21. Local therapy in stage I clear cell adenocarcinoma of the vagina
22. Pelvic exenteration in clear cell adenocarcinoma of the vagina and cervix
23. Influence of in utero diethystilbestrol exposure on the prognosis and biologic behavior of vaginal clear cell adenocarcinoma
24. Clear cell adenocarcinoma of the vagina and cervix secondary to intrauterine exposure to diethylstilbestrol
25. Males exposed in utero to diethylstilbestrol
26. Genital abnormalities and abnormal semen analyses in male patients exposed to diethylstilbestrol in utero
27. Natural killer cells in utero diethylstilbestrol exposed patients
28. Increased occurrence of autoimmune disease among women exposed in utero to diethylstilbestrol